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Rheumatoid arthritis (RA) is a chronic inflammatory disease
with a prevalence of approximately 1%. RA primarily affects
peripheral joints, where an inflammatory synovitis may
result in cartilage destruction, bone erosion, and ultimately
joint deformity and loss of joint function. The aetiology of
RA is unknown and the pathogenesis is only poorly under-
stood [1]. What is known is that certain major histocompat-
ibility complex (MHC) class II genes, in particular those
encoding the b-chain of the DR1 and DR4 molecules,
confer inherited susceptibility to RA [2]. The MHC associa-
tion strongly suggest that RA is an autoimmune T-cell
dependent disorder, in which the disease-associated MHC
class II molecules present autoantigenic peptides to
autoreactive T cells, that in turn mediate the inflammatory
process. The identity of the MHC class II bound autoanti-
gen(s) in RA is unknown, but collagen type II (CII) has been
a candidate primarily because it is the major protein com-
ponent of articular cartilage and because it can induce
arthritis in nonhumanized and humanized animal models of
RA [3]. The involvement of CII in RA has, however, had a
rather chequered history. Although there is now general
consensus that humoral immunity to CII is associated with
RA, it has been much more difficult to establish a direct
role for CII-reactive T cells in the pathogenesis of RA (for
example, see [4,5]). Moreover, treatment of RA patients
with oral CII has not been as successful as expected on
the basis of results obtained from similar trials in collagen-
induced arthritis in animals [6].
Reported in this issue of Arthritis Research, Berg et al [7]
have now reinvestigated T-cell reactivity to CII in RA
patients and in healthy control individuals, and have corre-
lated their findings to human leucocyte antigen (HLA)
class II type and anti-CII antibody levels in serum. To study
the in vitro T-cell response to CII, Berg et al measured
interferon-g production rather than T-cell proliferation after
CII stimulation of peripheral blood mononuclear cells. This
choice was based on a recent animal study [8] in which it
was suggested that CII is physiologically exposed to the
immune system, but only induces incomplete tolerization
and/or elimination of responding T cells because of its
restricted tissue expression. As a result, CII-reactive T
cells do not proliferate or proliferate only little, but secrete
cytokines when they are stimulated in vitro.
Berg  et al [7] found no difference in the interferon-g
response to CII between RA patients and the control
group. In contrast, there was a clear difference between
these two groups in their interferon-g responses to two
standard recall antigens (purified protein derivative and
killed influenza virus). Although the control group
responded well to the two antigens, the RA patients did
not, which may indicate that the RA patients have a
general T-cell hyporesponsiveness.
The basis of this apparently depressed T-cell function is
unknown, but has also been noted in earlier studies. Berg
et al speculated that it might further complicate the detec-
tion of a RA-associated T-cell response to CII, and re-eval-
uated their data after they had compensated for the low
T-cell responsiveness by using the T-cell responses to the
standard recall antigens as references. Interestingly, the
compensated interferon-g response to CII was significantly
higher in the RA group than in the control group, and was
highest in the group of patients carrying RA-associated
HLA class II alleles. When the authors compared the
serum levels of anti-CII antibodies with the interferon-g
response to CII they found an inverse correlation. Thishttp://arthritis-research.com/content/2/1/002
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observation was unexplained, but has also been noted in a
recent analogous study by Kim et al [9]. In that study, the
T-cell proliferative response to CII in peripheral blood and
synovial fluid was also analyzed. Even though the prolifera-
tive responses to CII were only modest, and thus under-
scoring the point made by Berg et al, they were found to
be higher in RA patients than in osteoarthritis patients and
healthy control individuals. In the RA patients, the T-cell
responses to CII were higher and more frequent in syn-
ovial fluid cells than in peripheral blood cells and were also
higher in early RA patients than in late RA patients. Kim et
al [9] also found that the T-cell proliferative response to a
CII-derived peptide corresponding to residues 255–274
was enhanced in RA patients and correlated well with that
to CII. This information is important because it has been
demonstrated, by using a humanized mouse model for RA,
that the DR4-restricted immunodominant T-cell epitope in
CII corresponds to amino acids 261–273 [10]. This is
interesting because this epitope fits the motif for peptides
binding RA-associated DR molecules [11]. Kim et al [9]
thus established that this epitope is also relevant to RA.
Taken together, the studies by Berg et al [7] and Kim et al
[9] demonstrate how difficult it is to study T-cell responses
to CII, but also that it is possible. It should now be possible
to analyze the T-cell response to CII and other candidate
autoantigens in more detail. From a mouse model of RA, it is
known that post-translational modifications, such as glyco-
sylation, of CII is of importance in the development of colla-
gen-induced arthritis [12]. Accordingly, it will be of interest
to study whether autoantigens modified by various enzymes
or proteases during synthesis or degradation also play a
role in RA. Moreover, it will be of importance to characterize
the T-cell response to CII and other potential autoantigens
at various stages of the disease, in order to achieve a thor-
ough understanding of potential intramolecular and inter-
molecular epitope spreading.
The studies by Berg et al [7] and Kim et al [9] support the
general view that T-cell responses to joint-specific
autoantigen(s) are of importance in the development of
RA. This classical concept is being challenged, however,
by three recent studies [13–15] from the laboratory of
Mathis and Benoist. This group has developed a new
mouse model that spontaneously develops an inflamma-
tory joint disease that is the result of systemic self-reactiv-
ity. The new model is based on a transgene encoded
T-cell receptor (TCR) that recognizes a self-component in
the context of the mouse MHC class II molecule I-Ag7 (for-
merly known as I-ANOD). When the TCR transgenic line
(KRN) is crossed with NOD mice that express I-Ag7 mole-
cules, 100% of the offspring expressing both the KRN
TCR and I-Ag7 molecules develop a severe inflammatory
arthritis. The arthritis begins when the animals are young,
3–4 weeks of age, and progresses rapidly. The inflamma-
tory process results in cartilage destruction, bone erosion
and ultimately joint deformity. The joint histopathology has
interesting similarities with both RA and experimental
arthritis in a number of different animal models [16]. No
other clinical manifestations or histological abnormalities
have been noted in the mice. The arthritis is clearly depen-
dent on and initiated by T-cell recognition of a ubiqui-
tiously expressed antigen presented by I-Ag7 molecules.
Once initiated, though, the disease is caused by
immunoglobulin G molecules. These molecules, however,
do not recognize CII. The target antigen for the initiating T
cells and the arthritogenic immunoglobulin G has now,
surprisingly, been identified as glucose-6-phosphate iso-
merase (GPI), which is a glycolytic enzyme that is
expressed in all tissues [15]. 
Because RA is a systemic disease, rather than a joint-spe-
cific disease, it seems likely that systemic self-reactivity
may also be the basis for the arthritic manifestations in
humans. It is unclear how reactivity to GPI in the animal
model actually leads to arthritis, however, and why there
are no additional extra-articular manifestations that are fre-
quent in RA. Mathis and Benoist have experimental evi-
dence that the basis for the joint disease is not simply
cross-reactivity with a joint-specific antigen. Instead they
suggest that leaky T-cell and B-cell tolerances to GPI,
perhaps combined with special features of synovial GPI
expression and/or unusual physiological features of the
joints, lead to an accumulation of immune complexes in the
joints and, in turn, arthritis, when a linked T-cell and B-cell
response towards GPI is initiated by an environmental or
stochastic genetic or physiological event. Why the arthritic
animals do not develop any of the extra-articular manifesta-
tions seen in RA patients is an open question, but it is inter-
esting that these manifestations in general occur in
patients with high concentrations of autoantibodies against
immunoglobulin G molecules (rheumatoid factors), which
are absent in the arthritic mice. Relatively limited genetic
heterogeneity in this animal model may also explain the
homogenous clinical appearance, because it known from
RA and other autoimmune diseases, including their respec-
tive animal models, that specific clinical phenotypes are
determined by genetic effects [17].
Given the impressive results of antitumour necrosis
factor-a therapy of patients with RA [18] and the new
promising results of interleukin-4 treatment of mice with
collagen-induced arthritis [19], one might wonder whether
it is worthwhile to investigate the initiating event(s) and the
target autoantigen(s) that are responsible for the initiation
and perpetuation for the inflammatory process in RA. The
answer is clearly ‘yes’, because only a detailed under-
standing of the disease process will provide the informa-
tion that is needed to develop a new generation of
anti-inflammatory drugs that act more specifically than the
ones currently in use. Thus, anticytokine therapy is a treat-
ment with potential serious side effects such as infections,Arthritis Research    Vol 2 No 1 Fugger
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including sepsis, and potentially also development of
tumours [20]. Therefore, the studies from Berg et al [7]
and Kim et al [9] that give support to the general idea that
immune responses against joint-specific antigens are of
critical importance in RA and the studies of Mathis and
Benoist [13–15] describing that joint-specific disease can
result from systemic autoreactivity provide an important
and challenging basis for the further unravelling of the
pathogenesis of RA.
To begin with, it will be interesting to study T-cell and B-
cell reactivity to GPI in RA patients at different stages of
disease and, if present, compare these parameters with
anti-CII reactivity. By doing this, it might be possible to
determine a potential temporal relationship between sys-
temic and joint-specific autoreactivity. Alternatively, these
two different forms of autoreactivity may either represent
different pathways to the same clinical manifestations, or
be associated with different clinical manifestations. It will
also be important to define the molecular basis for how
self-reactivity to GPI in the KRN TCR transgenic mice
leads to arthritis, and in more general terms to define the
rules for how systemic autoreactivity may lead to an
autoimmune (organ specific) disease.
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